1 方翼.3种氟喹诺酮类药物抗生素后效应的研究［J］.中国抗生素杂志，1997；22(1)：67 2 汪复. 氟喹诺酮类药物临床应用进展［J］. 中华内科杂志, 1999, 38：65. 3 Schaad UB, Stoupic C, Wedgwood KJ, et al. Clinical radiologic and magnetic resonance monitoring for skeletal toxicity in pediatric patients with cystic fibrosis receiving a threemonth course of ciprofloxacin［J］. Pediatr Infect Dis J, 1991, 10:723. 4 Rubio TT. Ciprofloxacin in the treatment of pseudomonas infection in children with cystic fibrosis［J］. Diag Microbiol Infect Dis, 1990, 13:153. 5 Schaad UB. Use of fluorquinolones in pediatrics:consensus report of an international society of chemotherapy commission［J］. Pediatr Infect Dis J, 1995, 14:1. 6 Schaad UB, Sander E, Wedgwood J, et al. Worphologic studies for skeletal toxicity after prolonged ciprofloxacin therpy in two juvenile cystic fibrosis patients［J］. Pediatr Infect Dis J, 1999, 37:47-48. 7 陶然.司帕沙星致日光性皮炎1例［J］.中国新药杂志，1999，8（6）：369. 8 吴荷芳.氟喹诺酮类药物不良反应分析［J］.中国医院药学杂志，1999，19（12）：765. 9 Paton JH,Reeves DS.Fluoroquinolone aptibiotics,microbiology,pharmacokinetics and clincial use［J］.Drugs,1988，36(2):193. 10 戴自英.实用抗菌药物学［M］.第2版.上海：上海科学技术出版社，1998.278. 11 聂青和，张开瑞.氟喹诺酮类抗菌药物不良反应的临床观察［J］.中级医刊，1993，5：45. 12 陈术辉.喹诺酮类抗菌药的联合药与不良反应［J］.湖南医学，1997，14(6)：369. 13 吴荷芳，王洪泽.氟喹诺酮类药物不良反应分析.中国医院药学杂志，1999，19(12)：65. 14 徐永昭.氧氟沙星的药物相互作用［J］.辽宁医学杂志，1996，10(2)：97. 15 徐镜海.环丙沙星与其它药物的相互作用［J］.武汉医学杂志，1996，20(3)：178. 16 刘洪云.环丙沙星合并用药的相互作用［J］.中国医院药学杂志，1996，16(10)：444. 17 Matuschka PR,Vissing RS.Clinafloxacin theophylline drug interac-tion［J］.Ann Rharmacother,1995,29(4):378. 18 Sarkar M,Polk RE,Guzelian PS,et al.In vitro effect of fluoro-quinolones on theophylline metabolism in human liver microsomes［J］.Antimicrob Agents chemother,1990,34(4):594. 19 Marchbanks CR.Drug interactions with fluoroquinolones［J］.Pharmacothera-py,1993,13(2pt2):235. 20 Hasegawa T,Nadai M,Apichartpichean R,et al.Pharmacokinetic characteristics of N7-substituted theophylline derivatives and their interaction with quinolone in rats［J］.J Pharm Sci,1991,80(10):962. 21 Fuhr U,Wolff T,Harder S,et al.Quinolone inhibition of cytochrome P-450-dependant caffeine metabolism in human liver microsomes［J］.Drug Metab Dispos,1990,18(6):1005. 22 Deppermann LM,Lode H,Fluoroquinolones:interaction profile during enteral absorption［J］.Drugs,1993,45 Suppl 3:65. 23 Deppermann LM,Lode H,Hoffken G,et al.Infucence of food ranitidine and antacids on the enteral absoption of ofleroxacin［J］.J Antimicrob chemother.submitted.1993,a 24 Janknegt R.Drug interaction with quinolones［J］.J Antimicrob Chemother,1990,26 Suppl D:7～29. 25 Lazzaroni m,Imbimbo BP,Bargiggia S,et al.Effects of magnesium-aluminum hydroxide antacid on absoption of rufloxacin.Antimicrob Agents Chemother［J］.1993,37(10):2212. 26 Marshall AJ, Piddock LJ,Interaction of divalent cations, quinolones and bacteria［J］.J-Antimicrob-Chemother,1994,34(4):465. 27 Deppermann KM,Lode H,Hoffken G,et al.Infuence of ferrous-sulfate on the bioavailability of ciproxacin and of loxacin［J］.Eur J Microbio,1993b.